Editas Medicine (EDIT) vs TRex Bio (TRXB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 12, 2026.
Summary
Editas Medicine is the larger company by market cap ($422.3 million vs $385.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Head-to-head
| Metric | EDIT | TRXB |
|---|---|---|
| Share price | $2.75 | $14.03 |
| Market cap | $422.35M | $385.06M |
| 1-day change | -5.17% | +0.21% |
| YTD return | +41.46% | — |
| 1-year return | -18.54% | — |
| 5-year return | -92.37% | — |
| EPS (TTM) | $-0.68 | $-2.47 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $40.52M | — |
| Revenue growth (YoY) | +25.39% | — |
| Net income (latest FY) | $-160.06M | — |
| Operating margin | -394.89% | — |
| Net margin | -395.01% | — |
| 52-week high | $4.33 | $15.50 |
| 52-week low | $1.66 | $13.50 |
| Distance from 52-week high | -36.49% | -9.48% |
| Analyst consensus | buy | — |
| Avg. price target upside | +114.55% | — |
| Average volume | 2.51M | 1.26M |
| Shares outstanding | 153.58M | 27.45M |
| Employees | 87 | 60 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Editas Medicine
EDIT stock →Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 87 employees
About TRex Bio
TRXB stock →TRex Bio, Inc. operates as a clinical-stage biopharmaceutical company that engages in discovery and development of immunoregulatory medicines.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 60 employees
EDIT vs TRXB FAQ
Which is bigger, Editas Medicine or TRex Bio?
Editas Medicine (EDIT) is larger, with a market capitalization of $422.35M compared with $385.06M for TRex Bio (TRXB).
Are Editas Medicine and TRex Bio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.